The use of flexible manufacturing capacity in pharmaceutical product introductions

Decision Sciences

Volumn 40, Issue 2, 2009, Pages 243-268

  Chambers, Chester G ^a   Snir, Eli M ^b   Ata, Asad ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

^c Southern Methodist University   (United States)

Author keywords

And Real Options; Flexible Capacity; Markov Decision Processes; Operations Strategy; Optimization; Pharmaceutical Manufacturing

Indexed keywords

EID: 65949104591     PISSN: 00117315     EISSN: 15405915     Source Type: Journal    
DOI: 10.1111/j.1540-5915.2009.00226.x     Document Type: Article

References (35)

1. Adams, C. P., Brantner, V. V. (2006). Estimating the cost of new drug development: Is it really $802 million? Health Affairs, 25 (2 420 428.
2. Bish, E. K., Muriel, A., Biller, S. (2005). Managing flexible capacity in a make-to-order environment. Management Science, 51 (2 167 180.
3. Bish, E. K., Wang, Q. (2004). Optimal investment strategies for flexible resources, considering pricing and correlated demands. Operations Research, 52 (6 954 964.
4. Carr, G. (1998). Survey: The pharmaceutical industry. The Economist, February 19, S1 S18.
5. Chan, J. (2007). Genzyme to construct new facility for Thymoglobulin. PharmaWatch: Biotechnology, 6 (7 20.
6. Dickinson, J. G. (2006). Slowdown in approvals not safety related: FDA. Medical Marketing & Media, 41 (12 15.
7. DiMasi, J. A. (1995). Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology & Therapeutics, 58 (1 1 14.
8. DiMasi, J. A. (2001). Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics, 69 (5 297 307. (Pubitemid 32477070)
9. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22 (2 151 185. (Pubitemid 36279392)
10. Dixit, A. K., Pindyck, R. S. (1994). Investment under uncertainty. Princeton, NJ : Princeton University Press.
11. Eapen, G. R. (2000). Pharmaceutical R&D investing: A real options approach. Proceedings of the Conference on How to Apply Real Options to Your Strategic Investment Decisions. Chicago, IL : IQPC, April 4-5.
12. Filar, J. A., Vrieze, K. (1997). Competitive markov decision processes. New York, NY : Springer-Verlag.
13. Grabowski, H. G., Vernon, J. M. (1990). A new look at the returns and risks to pharmaceutical R&D. Management Science, 36 (7 804 821.
14. Grabowski, H. G., Vernon, J. M. (1994). Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics, 13 (4 383 406.
15. Grabowski, H. G., Vernon, J. M., DiMasi, J. A. (2002). Returns on research and development for 1990s new drug introductions. PharmacoEconomics, 20 (3 11 29. (Pubitemid 35397395)
16. Graves, S. C., Tomlin, B. T. (2003). Process flexibility in supply chains. Management Science, 49 (7 907 919.
17. Jordan, W. C., Graves, S. C. (1995). Principles on the benefits of manufacturing process flexibility. Management Science, 41 (4 577 594.
18. Keyhani, S., Diener-West, M., Powe, N. (2006). Are development times for pharmaceuticals increasing or decreasing? Health Affairs, 25 (2 461 468.
19. Manufacturing Chemist 2007). AstraZeneca plans fundamental business changes, while Pfizer cuts jobs at UK plants. 78 (10 7.
20. Martinez, M. (2005). Pfizer to close Barceloneta's Cruce Davila injectable-operation plant, leaving 350 jobless. Caribbean Business, 33 (42 11 12.
21. Merck 1998). Annual report, 1998. Whitehouse Station, NJ : Author.
22. Myers, S. C., Howe, C. D. (1997). A life cycle financial model of pharmaceutical R&D. Working paper 41-97. Cambridge, MA : Sloan School of Management, Program on the Pharmaceutical Industry.
23. Ng, R. (2004). Drugs: From discovers to approval. Hobeken, NJ : Wiley.
24. Pharmaceutical Research and Manufacturers of America 2004). Industry profile 2004. Washington, DC : Author.
25. Pisano, G. P. (1997). The development factory: Unlocking the potential of process innovation. Boston, MA : Harvard Business School Publishing.
26. Pisano, G. P., Rossi, S. (1994). Eli Lilly and Company: The flexible facility decision - 1993. Harvard Business School Case Series, 9-694-074. Boston, MA : Harvard Business School Publishing.
27. Putterman, M. L. (1994). Markov decision processes: Discrete stochastic dynamic programming. Wiley Series in Probability and Mathematical Statistics. New York, NY : Wiley.
28. Raju, G. K., Cooney, C. L. (1995). 'Benchmarking' pharmaceutical manufacturing performance. Boston, MA : MIT's Program on the Pharmaceutical Industry.
29. Reepmeyer, G. (2006). Risk-sharing in the pharmaceutical industry. Heidelberg, Germany: Physica-Verlag Publishing.
30. Scherer, F. M. (1993). Pricing, profits, and technological progress in the pharmaceutical industry. Journal of Economic Perspectives, 7 (3 97 115.
31. Spradlin, T. (2000). Lessons about options from a pharmaceutical R&D project. Proceedings of the Conference on How to Apply Real Options to Your Strategic Investment Decisions. Chicago, IL : IQPC, April 4-5.
32. Torabzadeh, K. M., Woodruff, C. G., Sen, N. (1998). FDA Decisions on new drug applications and the market value of pharmaceutical firms. American Business Review, 12 (2 42 51.
33. U.S. Congress, Office of Technology Assessment 1993). Pharmaceutical R&D: Costs, risks and rewards, OTA-H-522. Washington, DC : U.S. Government Printing Office.
34. Van Mieghem, J. A. (1998). Investment strategies for flexible resources. Management Science, 44 (8 1071 1078. (Pubitemid 128569652)
35. Van Mieghem, J. A. (2003). Capacity management, investment, and hedging: Review and recent developments. Manufacturing & Service Operations Management, 5 (4 269 302.